Micromagnetic-microfluidic blood cleansing device

被引:151
作者
Yung, Chong Wing [1 ,2 ]
Fiering, Jason [3 ]
Mueller, Andrew J. [3 ]
Ingber, Donald E. [1 ,2 ,4 ]
机构
[1] Childrens Hosp, Dept Surg & Pathol, Vasc Biol Program, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Charles Stark Draper Lab Inc, Cambridge, MA 02138 USA
[4] Harvard Univ, Sch Engn & Appl Sci, Wyss Inst Biologically Inspired Engn, Cambridge, MA 02139 USA
关键词
SEVERE SEPSIS; FLOW; EPIDEMIOLOGY; SEPARATION; VISCOSITY; CELLS; DRUG;
D O I
10.1039/b816986a
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is a lethal disease caused by a systemic microbial infection that spreads via the bloodstream to overwhelm the body's defenses. Current therapeutic approaches are often suboptimal, in part, because they do not fully eliminate the pathogen, and hence the source of deadly toxins. Here we describe an extracorporeal blood cleansing device to selectively remove pathogens from contaminated blood and thereby enhance the patient's response to antibiotic therapy. Immunomagnetic microbeads were modified to create magnetic opsonins that were used to cleanse flowing human whole blood of Candida albicans fungi, a leading cause of sepsis-related deaths. The micromagnetic-microfluidic blood cleansing device generates magnetic field gradients across vertically stacked channels to enable continuous and high throughput separation of fungi from flowing whole blood. A multiplexed version of the device containing four parallel channels achieved over 80% clearance of fungi from contaminated blood at a flow rate of 20 mL/h in a single pass, a rate 1000 times faster than a previously described prototype micromagnetic-microfluidic cell separation system. These results provide the first proof-of-principle that a multiplexed micromagnetic-microfluidic separation system can be used to cleanse pathogens from flowing human blood at a rate and separation efficiency that is relevant for clinical applications.
引用
收藏
页码:1171 / 1177
页数:7
相关论文
共 41 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Asanuma Y, 1989, ASAIO Trans, V35, P343, DOI 10.1097/00002480-198907000-00055
  • [3] Bailey D. D., 1986, BIOCH ENG FUNDAMENTA
  • [4] Becker H, 2008, Med Device Technol, V19, P21
  • [5] Berger M, 2001, ELECTROPHORESIS, V22, P3883, DOI 10.1002/1522-2683(200110)22:18<3883::AID-ELPS3883>3.0.CO
  • [6] 2-4
  • [7] BLANKENSTEIN G, 1997, MICROFABRICATED FLOW
  • [8] Hemofiltration in sepsis and systemic inflammatory response syndrome: The role of dosing and timing
    Bouman, Catherine S. C.
    Straaten, Heleen M. Oudemans-van
    Schultz, Marcus J.
    Vroom, Margreeth B.
    [J]. JOURNAL OF CRITICAL CARE, 2007, 22 (01) : 1 - 12
  • [9] The immunopathogenesis of sepsis
    Cohen, J
    [J]. NATURE, 2002, 420 (6917) : 885 - 891
  • [10] Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia
    Coopersmith, CM
    Amiot, DM
    Stromberg, PE
    Dunne, WM
    Davis, CG
    Osborne, DF
    Husain, KD
    Turnbull, IR
    Karl, IE
    Hotchkiss, RS
    Buchman, TG
    [J]. SHOCK, 2003, 19 (05): : 408 - 414